CV Sciences Inc (CVSI)

[Wolf-man jack]

WQLF SAYS: The itsy bitsy spider Web bashtard needs to look no further to find the True definition of a QUAGMIRE YQU Now Understand YQU Understand. YQU will not find it on their Pump Up The Volume lonesome message board. LoLlipops 🍭 🍭. Have Mercy WQLF ahoooooo

Message in reply to: Nowwhatwo 🧌
Quagmire.
Figuratively, it refers to a complex, hazardous, or difficult situation that is hard to escape or resolve

Here is the True Definition of a QUAGMIRE.

Quagmire.

https://www.ainvest.com/news/charlotte-web-efsa-safety-rejection-turns-cms-medicare-pilot-binary-legal-gamble-2605/

https://finance.yahoo.com/sectors/healthcare/articles/candy-coated-costs-unvalidated-hemp-163500945.html

https://www.morningstar.com/news/accesswire/1165298msn/judge-takes-cms-hemp-marijuana-cbd-program-under-advisement-as-evidence-mounts-that-medicare-may-be-moving-ahead-of-fda-science

Dr. Joong J Fang Said: If this case has any muster, look for CV SCIENCES to be on board as a Better Choice for the Medicare Pilot Program. It appears from the Earnings Conference Call, CV SCIENCES CEO Joseph Dowling is aware of the Quagmire that the itsy bitsy spider Web company is in. Apparently, that is why their Stock is Quickly going down the water Spout.

Ai Generated:

Yes, CV Sciences (makers of PlusCBD) has some of the most robust safety data and toxicology studies in the CBD industry. They are recognized as the first hemp extract brand to secure a self-affirmed Generally Recognized as Safe (GRAS) status, backed by comprehensive pre-clinical testing.

A breakdown of their safety and toxicology research includes:

Self-Affirmed GRAS Status: In 2018, CV Sciences completed a rigorous non-clinical testing and toxicological program to achieve GRAS status, the FDA's standard for food safety presumption.

Published Toxicology Studies: They have published non-clinical and toxicology studies validating the safety of their full-spectrum hemp extract.

Post-Market Surveillance: They published a 2-year longitudinal safety study analyzing adverse event reports from over 5 million product units sold. Only 0.03% of units resulted in mild, transient reported adverse events (mostly gastrointestinal or dermatological), with no liver toxicity reported.

Clinical Trials: Their formulas have been evaluated through randomized, placebo-controlled clinical trials to test for efficacy, tolerance, and human safety.

Joseph Dowling Said:

"We did have some good news recently at the federal level . On April 1, 2026, the Centers for Medicare and Medicaid Services introduced the Substance Access Beneficiary Engagement Incentive.for eligible participants in select CMS innovation center models. The program allows approved participants subject to CMS requirements and oversight to provide eligible beneficiaries with up to $500.annually in qualifying hemp derived products. Participating organizations purchase and provide the products directly to patients. CMS guidance states that eligible products include non intoxicating full spectrum CBD products with up to 3 milligrams of naturally occurring THC per serving. In addition, the FDA issued a Limited Enforcement Discretion Letter covering eligible orally administered hemp derived CBD products provided under certain health care program conditions, which we believe provides additional clarity! During Q1 we focused on preparing for this new healthcare channel!"

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177607002


Wolfman Jack Said: Have You heard about the Lonesome Troller You Now Understand You Understand.. NowWHAT You Gonna Do..Have Mercy ahoooooo